Reuters logo
BRIEF-Ultragenyx completes patients dosing in first cohort of phase 1/2 study of DTX301
November 16, 2017 / 1:42 PM / a month ago

BRIEF-Ultragenyx completes patients dosing in first cohort of phase 1/2 study of DTX301

Nov 16 (Reuters) - Ultragenyx Pharmaceutical Inc

* Ultragenyx announces completion of patient dosing in first cohort of phase 1/2 clinical study of dtx301 gene therapy in ornithine transcarbamylase (OTC) deficiency

* Ultragenyx Pharmaceutical Inc - ‍initial data from the first cohort of three patients is expected in early 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below